---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-24-000010"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2024-02-01T23:59:59+00:00"
generated_at: "2026-06-06T10:51:14.067886+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kiora Pharmaceuticals announces $15M private placement with potential $30M from warrant exercises

## Summary
- Upfront gross proceeds of $15M from sale of shares and pre-funded warrants at $0.5524 per unit.
- Tranche A warrants (24.7M shares, $0.6076 exercise) tied to KIO-301 Phase 2 data; Tranche B tied to KIO-104 Phase 2.
- Participating investors include ADAR1 Capital, Nantahala Capital, Rosalind Advisors, Stonepine Capital, Velan Capital.
- Net proceeds to fund KIO-104 development for posterior non-infectious uveitis and general operations.
- Closing expected on or about February 5, 2024, subject to customary conditions.

## SEC filing metadata
- accession: 0001372514-24-000010
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2024-02-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000010/0001372514-24-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000010/kprx-20240131.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-24-000010
- JSON: https://secwatch.observer/filing/0001372514-24-000010.json
- Plain text: https://secwatch.observer/filing/0001372514-24-000010.txt

## Key facts
- Material Agreements
  KIORA PHARMACEUTICALS INC entered into Securities Purchase Agreement with certain institutional investors valued at approximately $15.0 million (effective 2024-01-31).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: approximately $15.0 million
  - Effective: 2024-01-31
  source text: On January 31, 2024, Kiora Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors (the “Purchasers”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000010/0001372514-24-000010-index.htm
- Material Agreements
  KIORA PHARMACEUTICALS INC entered into Placement Agency Agreement with Maxim Group LLC (effective 2024-01-31).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Maxim Group LLC
  - Effective: 2024-01-31
  source text: On January 31, 2024 and in connection with the Securities Purchase Agreement, the Company entered into a customary placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (“Maxim”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000010/0001372514-24-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.